Back to News
Market Impact: 0.25
Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
Source: PR Newswire
Healthcare & Biotech
Accro Bioscience announced that it dosed the first patient in a Phase IIb clinical trial for a novel therapeutic targeting immune-mediated diseases. The trial initiation represents a positive clinical-development milestone, although the release provides no efficacy, safety, financial, or enrollment details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- Why is Telix Pharmaceuticals stock sliding today?
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
- GE Aerospace Goes Vertical (Integration)
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder
- Why India’s Big Tech Companies Are Betting on Hyderabad